Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-U01 Substudy 01A of zilovertamab vedotin in pediatric and young adult cancers
2023-507178-41-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 2, open-label trial of zilovertamab vedotin in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) and 2 more (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants from 1 to <18 years of age who experience a dose-limiting toxicity, Number of participants from 1 to <18 years of age who experience one or more adverse events and 4 more. Planned start Nov 2024; status: authorised.
02
Drugs
zilovertamab vedotin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)neuroblastomaEwing sarcoma
Beyond the preview
Go deeper on 2023-507178-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507178-41-00.